Senseonics Holdings (SENS) Misses Q2 EPS by 9c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Senseonics Holdings, Inc. Reports Second Quarter 2018 Financial Results
August 8, 2018 4:10 PM EDTGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the second quarter ended June 30, 2018.
RECENT HIGHLIGHTS & ACCOMPLISHMENTS:
Received FDA approval for the Eversense® CGM System, the first and only long-term implantable continuous glucose monitoring system Completed first commercial insertion in the U.S. Secured first U.S. payor coverage of Eversense from Horizon... More